Clinical Trials
6 trialsNCT06466798 2026-01-08
Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies
The University of Texas Health Science Center, Houston
Phase 1 Withdrawn
NCT05823480 2024-09-19
Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS
City of Hope Medical Center
Phase 1 Withdrawn
NCT05720988 2024-03-08
Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT04128020 2020-10-12
Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia
Big Ten Cancer Research Consortium
Phase 1 Withdrawn
NCT03612739 2019-10-29
EPITHINK
Celyad Oncology SA
Phase 1 Withdrawn
NCT00842582 2016-11-02
Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer
Loyola University
Phase 1 Withdrawn